| TP53 is a critical gene within the 17p13 minimally deleted region and is a haploinsufficient tumor suppressor in myeloma | None |
| Interaction is demonstrated between ZASP and two new binding partners both of which have roles in signalling, regulation of gene expression and muscle differentiation; the mechanosensing protein Ankrd2 and the tumour suppressor protein p53. | None |
| DRAGO (drug-activated gene overexpressed) KIAA0247 represents a new p53-dependent gene highly regulated in human cells and whose expression cooperates with p53 in tumor suppressor functions. | None |
| An intronic promoter and two novel exons have been identified resulting in the expression of multiple transcripts and protein isoforms. These regions are additional targets for mutation events impairing the tumor suppressive activity of TP53 | None |
| We document an apparent role of FOXP1 and TP63, up to now poorly documented, in the progression of MDS in our patient who is lacking mutations in the TP53 tumor suppressor gene normally associated with poor outcome in myelodysplastic syndrome with 5q-. | None |
| Degradation of p53 protein induced by bacterial CagA protein is controlled by the P14ARD tumor suppressor. Two host E3 ubiquitin ligases, ARF-BP1 and HDM2, are involved in this process. | None |
| Results revealed an important role and mechanism of p53 in antagonizing the stimulating effect of hypoxia on glycolysis, which contributes to p53_s function in tumor suppression. | None |
| Data suggest that ribosomal protein S27-like (Rps27l) is an essential gene for postnatal development by modulating tumor suppressor protein p53. | None |
| binding mode of the phosphorylated transactivation domain of tumor suppressor p53 | None |
| Our data suggest that LCE1 is a novel p53 downstream target that can be directly transactivated by p53 and is likely to have tumor suppressor functions through modulation of the PRMT5 activity. | None |
| protein levels of the tumor suppressor p53 and its targets, p21 and MDM2, were increased in LNCaP and bicalutamide-resistant LNCaP cells treated with RPL31 siRNA. | None |
| Data indicate that tumor suppressor P53 can suppress canonical Hedgehog signaling via induction of patched domain containing 4 (PTCH53), a PTCH1 homolog. | None |
| Localization of cellular tumor suppressor p53. | None |
| The results reveal genome-wide and cell type-specific alterations in miRNA expression during the human DNA damage response, which are regulated by the tumor suppressor protein p53. | None |
| USP24 deubiquitinase regulates the DNA damage response by directly targeting the p53 tumor suppressor. | None |
| show that REV1 is a novel binding partner of the tumor suppressor p53 and regulates its activity | None |
| ectopically expressed SHIP1 accumulates in nucleolar cavities and colocalizes with the tumor suppressor protein p53. | None |
| Our findings show that Delta133p53beta supports CSC potential. Moreover, they indicate that the TP53 gene, which is considered a major tumor suppressor gene, also acts as an oncogene via the Delta133p53beta isoform. | None |
| findings uncover a new mode of tumour suppression based on p53 regulation of cystine metabolism, ROS responses and ferroptosis | None |
| Studies suggest partial confirmation of the association between the tumor suppressor protein p53 (TP53) Arg72Pro polymorphism and cancer risk susceptibility. | None |